
    
      This is a phase II clinical trial. The purpose of this research is to study the safety and
      efficacy of Camrelizumab treating patients with newly diagnosed glioblastomas. Neoadjuvant
      PD-1 inhibitor will be administered to patients with newly diagnosed glioblastomas, followed
      by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment.
    
  